A detailed history of Geode Capital Management, LLC transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 3,045,361 shares of HRTX stock, worth $4.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,045,361
Previous 3,112,335 2.15%
Holding current value
$4.81 Million
Previous $10.9 Million 44.37%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$1.73 - $3.67 $115,865 - $245,794
-66,974 Reduced 2.15%
3,045,361 $6.06 Million
Q2 2024

Aug 09, 2024

BUY
$2.32 - $3.86 $733,621 - $1.22 Million
316,216 Added 11.31%
3,112,335 $10.9 Million
Q1 2024

May 13, 2024

BUY
$1.71 - $3.06 $293,170 - $524,621
171,445 Added 6.53%
2,796,119 $7.75 Million
Q4 2023

Feb 13, 2024

BUY
$0.54 - $1.82 $123,937 - $417,713
229,513 Added 9.58%
2,624,674 $4.46 Million
Q3 2023

Nov 13, 2023

BUY
$0.97 - $1.8 $330,512 - $613,323
340,735 Added 16.59%
2,395,161 $2.47 Million
Q2 2023

Aug 11, 2023

BUY
$1.11 - $2.88 $88,213 - $228,879
79,472 Added 4.02%
2,054,426 $2.38 Million
Q1 2023

May 15, 2023

BUY
$1.51 - $3.25 $24,933 - $53,664
16,512 Added 0.84%
1,974,954 $2.98 Million
Q4 2022

Feb 13, 2023

BUY
$2.25 - $4.67 $297,321 - $617,107
132,143 Added 7.24%
1,958,442 $4.9 Million
Q3 2022

Nov 14, 2022

BUY
$2.66 - $5.37 $36,348 - $73,381
13,665 Added 0.75%
1,826,299 $7.71 Million
Q2 2022

Aug 12, 2022

BUY
$2.3 - $6.29 $387,030 - $1.06 Million
168,274 Added 10.23%
1,812,634 $5.06 Million
Q1 2022

May 13, 2022

SELL
$4.63 - $9.94 $311,358 - $668,445
-67,248 Reduced 3.93%
1,644,360 $9.41 Million
Q4 2021

Feb 11, 2022

BUY
$8.35 - $12.6 $828,595 - $1.25 Million
99,233 Added 6.15%
1,711,608 $15.6 Million
Q3 2021

Nov 12, 2021

BUY
$10.13 - $15.0 $232,817 - $344,745
22,983 Added 1.45%
1,612,375 $17.2 Million
Q2 2021

Aug 13, 2021

BUY
$13.27 - $18.48 $1.97 Million - $2.74 Million
148,247 Added 10.29%
1,589,392 $24.7 Million
Q1 2021

May 12, 2021

BUY
$14.49 - $20.72 $1.98 Million - $2.83 Million
136,474 Added 10.46%
1,441,145 $23.4 Million
Q4 2020

Feb 12, 2021

BUY
$14.61 - $22.14 $692,236 - $1.05 Million
47,381 Added 3.77%
1,304,671 $27.6 Million
Q3 2020

Nov 13, 2020

SELL
$13.67 - $17.77 $148,948 - $193,621
-10,896 Reduced 0.86%
1,257,290 $18.6 Million
Q2 2020

Aug 13, 2020

BUY
$10.89 - $21.47 $660,750 - $1.3 Million
60,675 Added 5.02%
1,268,186 $18.7 Million
Q1 2020

May 14, 2020

BUY
$10.23 - $24.56 $769,817 - $1.85 Million
75,251 Added 6.65%
1,207,511 $14.2 Million
Q4 2019

Feb 13, 2020

BUY
$17.42 - $26.61 $3.66 Million - $5.59 Million
210,035 Added 22.77%
1,132,260 $26.6 Million
Q3 2019

Nov 12, 2019

BUY
$16.36 - $21.39 $411,372 - $537,851
25,145 Added 2.8%
922,225 $17.1 Million
Q2 2019

Aug 14, 2019

BUY
$16.93 - $26.22 $1.39 Million - $2.15 Million
81,852 Added 10.04%
897,080 $16.7 Million
Q1 2019

May 14, 2019

BUY
$23.15 - $28.34 $1.48 Million - $1.81 Million
63,978 Added 8.52%
815,228 $19.9 Million
Q4 2018

Feb 13, 2019

BUY
$22.03 - $32.01 $582,230 - $845,992
26,429 Added 3.65%
751,250 $19.5 Million
Q3 2018

Nov 13, 2018

BUY
$30.0 - $40.85 $2.32 Million - $3.15 Million
77,210 Added 11.92%
724,821 $22.9 Million
Q2 2018

Aug 14, 2018

BUY
$26.4 - $42.0 $4.54 Million - $7.22 Million
171,911 Added 36.14%
647,611 $25.2 Million
Q1 2018

May 15, 2018

BUY
$18.43 - $28.8 $1.44 Million - $2.25 Million
78,244 Added 19.69%
475,700 $13.1 Million
Q4 2017

Feb 13, 2018

BUY
$14.8 - $18.85 $35,668 - $45,428
2,410 Added 0.61%
397,456 $7.19 Million
Q3 2017

Nov 14, 2017

BUY
$14.65 - $16.85 $123,353 - $141,877
8,420 Added 2.18%
395,046 $6.38 Million
Q2 2017

Aug 14, 2017

BUY
N/A
386,626
386,626 $5.35 Million

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $188M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.